

Contents

1	Introduction to Clinical Trials	1
	Fundamental Point	2
	What Is a Clinical Trial?	2
	Clinical Trial Phases	4
	Phase I Studies	5
	Phase II Studies	7
	Phase III/IV Trials	9
	Why Are Clinical Trials Needed?	10
	Problems in the Timing of a Trial	14
	Study Protocol	15
	Appendices	17
	References	18
2	Ethical Issues	25
	Fundamental Point	27
	Planning and Design	27
	Ethics Training	27
	Does the Question Require a Clinical Trial?	27
	Randomization	30
	Control Group	31
	Protection from Conflicts of Interest	33
	Informed Consent	34
	Conduct	37
	Trials in Low- and Middle-Income Countries	37
	Recruitment	38
	Safety and Efficacy Monitoring	39
	Early Termination for Other Than Scientific or Safety Reasons	40
	Privacy and Confidentiality	41
	Data Falsification	41

Reporting	42
Publication Bias, Suppression, and Delays	42
Conflicts of Interest and Publication	43
References	43
3 What Is the Question?	49
Fundamental Point	50
Selection of the Questions	50
Primary Question	50
Secondary Questions Regarding Benefit	51
Questions Regarding Harm	52
Ancillary Questions	53
Kinds of Trials	54
Trials with Extensive Data Collection vs. Large, Simple	54
Superiority vs. Noninferiority Trials	55
Comparative Effectiveness Trials	55
Intervention	56
Response Variables	57
Kinds of Response Variables	57
Specifying the Question	60
Biomarkers and Surrogate Response Variables	62
Changing the Question	65
General Comments	66
References	67
4 Study Population	73
Fundamental Point	73
Definition of Study Population	74
Considerations in Defining the Study Population	75
Potential for Benefit	76
High Likelihood of Showing Benefit	78
Avoiding Adverse Effects	80
Competing Risk	81
Avoiding Poor Adherers	81
Pharmacogenetics	82
Generalization	83
Recruitment	85
References	86
5 Basic Study Design	89
Fundamental Point	90
Overview	90
Randomized Control Trials	92

	Nonrandomized Concurrent Control Studies	94
	Historical Controls and Databases	95
	Strengths of Historical Control Studies	95
	Limitations of Historical Control Studies	96
	Role of Historical Controls	100
	Cross-Over Designs	102
	Withdrawal Studies	103
	Factorial Design	104
	Group Allocation Designs	106
	Hybrid Designs	107
	Large, Simple and Pragmatic Clinical Trials	107
	Studies of Equivalency and Noninferiority	109
	Adaptive Designs	114
	References	115
6	The Randomization Process	123
	Fundamental Point	123
	Fixed Allocation Randomization	124
	Simple Randomization	125
	Blocked Randomization	126
	Stratified Randomization	128
	Adaptive Randomization Procedures	131
	Baseline Adaptive Randomization Procedures	132
	Minimization	133
	Response Adaptive Randomization	135
	Mechanics of Randomization	137
	Recommendations	139
	Appendix: Adaptive Randomization Algorithm	139
	References	141
7	Blinding	147
	Fundamental Point	148
	Who Is Blinded?	148
	Types of Blinding	148
	Unblinded	148
	Single-Blind	150
	Double-Blind	151
	Triple-Blind	153
	Protecting the Double-Blind Design	154
	Matching of Drugs	155
	Coding of Drugs	157
	Official Unblinding	158
	Inadvertent Unblinding	159
	Assessment and Reporting of Blinding	160
	Debriefing of Participants	161
	References	162

8	Sample Size	165
	Fundamental Point	166
	Statistical Concepts	167
	Dichotomous Response Variables	171
	Two Independent Samples	171
	Paired Dichotomous Response	177
	Adjusting Sample Size to Compensate for Nonadherence	178
	Sample Size Calculations for Continuous Response Variables	179
	Two Independent Samples	180
	Paired Data	181
	Sample Size for Repeated Measures	183
	Sample Size Calculations for “Time to Failure”	184
	Sample Size for Testing “Equivalency” or Noninferiority of Interventions	188
	Sample Size for Cluster Randomization	189
	Multiple Response Variables	192
	Estimating Sample Size Parameters	193
	References	195
9	Baseline Assessment	201
	Fundamental Point	201
	Uses of Baseline Data	201
	Description of Trial Participants	201
	Baseline Comparability	202
	Controlling for Imbalances in the Analysis	204
	Subgrouping	205
	What Constitutes a True Baseline Measurement?	207
	Screening for Participants	207
	Regression Toward the Mean	208
	Interim Events	210
	Uncertainty About Qualifying Diagnosis	210
	Contamination of the Intervention	211
	Changes of Baseline Measurement	212
	References	213
10	Recruitment of Study Participants	215
	Fundamental Point	215
	Considerations Before Participant Enrollment	216
	Selection of Study Sample	216
	Common Recruitment Problems	217
	Planning	219
	Recruitment Sources	221
	Conduct	223
	Monitoring	225
	Approaches to Lagging Recruitment	229
	References	230

11 Data Collection and Quality Control	233
Fundamental Point	234
Problems in Data Collection	235
Major Types	235
Minimizing Poor Quality Data	238
Design of Protocol and Manual	238
Development of Forms and Data Entry Tools	239
Training and Certification	239
Pretesting	241
Techniques to Reduce Variability Including Central Adjudication of Events	241
Data Entry	243
Electronic Source Data	243
Quality Monitoring	244
Monitoring of Data	246
Monitoring of Procedures	246
Monitoring of Drug Handling	247
Audits	248
References	250
12 Assessment and Reporting of Harm	255
Fundamental Point	256
Assessment of Harm	256
Strengths	256
Limitations	257
Identification of Harm in Clinical Trials	259
Classification of Adverse Events	260
Ascertainment	262
Prespecified Adverse Events	263
Characteristics of Adverse Events	264
Length of Follow-up	264
Analyzing Adverse Events	266
Standard Reporting	266
Prespecified Analysis	267
Post Hoc Analysis	267
Meta-analysis	268
Reporting of Harm	269
Scientific Journal Publication	271
Regulatory Considerations	272
Recommendations for Assessing and Reporting Harm	273
References	274
13 Assessment of Health Related Quality of Life	279
Fundamental Point	279
Types of HRQL Measures	280

Primary Measures	280
Additional Measures	281
Uses of HRQL Measures	282
Methodological Issues	284
Design Issues	284
Study Population	285
Type of Intervention	285
Frequency of Assessment (Acute Versus Chronic)	286
Protocol Considerations	287
Modifying and Mediating Factors	288
Selection of HRQL Instruments	288
Types of Measures	289
Scoring of HRQL Measures	290
Determining the Significance of HRQL Measures	290
Utility Measures/Preference Scaling and Comparative Effectiveness Research	291
References	292
14 Participant Adherence	297
Fundamental Point	298
Definitions	298
Medication Adherence	299
Considerations Before Participant Enrollment	300
Design Factors	300
Participant Factors	302
Maintaining Good Participant Adherence	306
Adherence Monitoring	311
Dealing with Low Adherence	314
Special Populations	315
References	315
15 Survival Analysis	319
Fundamental Point	319
Estimation of the Survival Curve	320
Cutler-Ederer Estimate	324
Kaplan-Meier Estimate	324
Comparison of Two Survival Curves	328
Point-by-Point Comparison	329
Comparison of Median Survival Times	329
Total Curve Comparison	330
Generalizations	335
Covariate Adjusted Analysis	337
References	340

16	Monitoring Committee Structure and Function	343
	Fundamental Point	346
	Monitoring Committee	346
	Repeated Testing for Significance	350
	Decision for Early Termination	352
	Decision to Extend a Trial	363
	Accelerated Approval Paradigm	367
	References	368
17	Statistical Methods Used in Interim Monitoring	373
	Fundamental Point	373
	Classical Sequential Methods	374
	Group Sequential Methods	375
	Flexible Group Sequential Procedures:	
	Alpha Spending Functions	378
	Applications of Group Sequential Boundaries	381
	Asymmetric Boundaries	384
	Curtailed Sampling and Conditional	
	Power Procedures	386
	Other Approaches	391
	Trend Adaptive Designs and Sample Size Adjustments	392
	References	395
18	Issues in Data Analysis	403
	Fundamental Point	404
	Which Participants Should Be Analyzed?	404
	Ineligibility	406
	Nonadherence	410
	Missing or Poor Quality Data	414
	Competing Events	421
	Composite Outcomes	422
	Covariate Adjustment	424
	Surrogates as a Covariate	425
	Baseline Variables as Covariates	428
	Subgroup Analyses	431
	Not Counting Some Events	438
	Comparison of Multiple Variables	439
	Use of Cutpoints	440
	Noninferiority Trial Analysis	442
	Analysis Following Trend Adaptive Designs	444
	Meta-analysis of Multiple Studies	445
	Rationale and Issues	445
	Statistical Methods	449
	Analysis for Harmful Effects	451
	References	453

19	Closeout	463
	Fundamental Point	463
	Termination Procedures	463
	Planning	463
	Scheduling of Closeout Visits	464
	Final Response Ascertainment	465
	Transfer of Post-trial Care	468
	Data and Other Study Material	469
	Cleanup and Verification	469
	Storage	470
	Dissemination of Results	471
	Post Study Follow-up	473
	References	475
20	Reporting and Interpreting of Results	479
	Fundamental Point	480
	Guidelines for Reporting	480
	Authorship	482
	Duplicate Publication	483
	Disclosure of Conflict of Interest	483
	Presentation of Data	483
	Interpretation	484
	Publication Bias	485
	Did the Trial Work as Planned?	487
	Baseline Comparability	487
	Blinding	487
	Adherence and Concomitant Treatment	488
	What Are the Limitations?	488
	What Kinds of Analyses?	489
	How Do the Findings Compare with Those from Other Studies?	491
	What Are the Clinical Implications of the Findings?	492
	Data Sharing	493
	References	494
21	Multicenter Trials	501
	Fundamental Point	502
	Reasons for Multicenter Trials	502
	Conduct of Multicenter Trials	504
	Globalization of Trials	511
	Large, Simple Trials	514
	References	515
22	Regulatory Issues	519
	Fundamental Point	520
	Background	521

Overview	521
History	521
Regulatory Requirements	523
Trial Phases	523
Pretrial Requirements	525
Conduct	526
Interventions: Drugs	528
Interventions: Devices	529
Interventions: Biologics	532
Post-trial Requirements	533
Documents for FDA submission	534
Advisory Committee Meeting	535
Post-approval Issues and Postmarketing Investigations	535
Key Links	537
International Conference on Harmonisation	537
U.S. Food and Drug Administration	537
European Medicines Agency	538
Health Canada	538
Pharmaceuticals and Medical Devices Agency, Japan	538
Bioethics Resources	538
References	538
Index	543